IFNA14 Human

IFN-α14 is produced by recombinant DNA technology, typically using mammalian cells like human embryonic kidney (HEK293) cells . The recombinant form is expressed and purified to ensure high purity and biological activity. The molecular mass of IFN-α14 is approximately 22 kDa .

IFN-α14, like other type I interferons, binds to a common heterodimer receptor composed of IFNAR1 and IFNAR2 subunits . This binding activates the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling pathway, leading to the formation of the ISGF3 transcriptional complex (STAT1/STAT2/IRF9) . ISGF3 then binds to interferon-stimulated response elements (ISRE) in the promoters of numerous interferon-stimulated genes (ISGs), inducing their expression .

The primary functions of IFN-α14 include:

• Antiviral Activity: IFN-α14 inhibits viral replication within host cells by inducing the expression of ISGs that interfere with various stages of the viral life cycle .
• Immunomodulation: It enhances the immune response by increasing the activity of natural killer (NK) cells and macrophages, and by promoting the differentiation of T cells .
• Antiproliferative Effects: IFN-α14 can inhibit the proliferation of various cell types, including tumor cells, by inducing cell cycle arrest and apoptosis .

Recombinant IFN-α14 is used in various research applications, including:

• Cellular Assays: It is used to study the antiviral and immunomodulatory effects of interferons in vitro .
• ELISA: Enzyme-linked immunosorbent assays (ELISA) utilize IFN-α14 to detect and quantify specific proteins or antibodies .

Recombinant human IFN-α14 is typically lyophilized and should be stored at -20°C for long-term stability . Upon reconstitution, it should be aliquoted and stored at -80°C to avoid repeated freeze-thaw cycles .